All Brands Owned by H. Lundbeck A/S

What does Lundbeck own?
Lundbeck owns a portfolio of central nervous system pharmaceutical brands including Vyepti for migraine, Rexulti for schizophrenia and depression, Trintellix for depression, Abilify Maintena for schizophrenia, and Northera for neurogenic orthostatic hypotension. The company also owns desmoteplase, an investigational stroke drug whose development was discontinued after failed clinical trials, and bexicaserin, an investigational epilepsy treatment in phase III trials.

Is Lundbeck publicly traded?
Yes, H. Lundbeck A/S trades on Nasdaq Copenhagen under ticker LUN. The company has two share classes: HLUN A shares with voting rights and HLUN B shares without voting rights. The Lundbeck Foundation owns approximately 70% of shares. Lundbeck was listed on the Copenhagen Stock Exchange in 1999.

Who founded Lundbeck?
Lundbeck was founded on August 14, 1915 by Hans Lundbeck as a trading company in Copenhagen. The business initially supplied machinery, aluminum foil, artificial sweeteners, and photographic equipment. Hans Lundbeck died in 1943, and his wife Grete Lundbeck took over leadership in 1950, guiding the company through a period of significant growth and establishing the Lundbeck Foundation in 1954.

What is Lundbeck's main business?
Lundbeck focuses exclusively on brain diseases, developing treatments for depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, and epilepsy. The company researches, develops, manufactures, and sells pharmaceuticals for these neurological and psychiatric conditions. Its key growth products are Vyepti for migraine and Rexulti for schizophrenia and depression.

What happened to desmoteplase?
Desmoteplase was an investigational thrombolytic drug for acute ischemic stroke. Lundbeck purchased all remaining rights from PAION AG in 2012 for 20 million euros. The DIAS-3 phase III trial did not demonstrate significant clinical benefit, and the DIAS-4 trial was prematurely terminated after the DIAS-3 results. A pooled analysis of DIAS-3, DIAS-4, and DIAS-J showed no statistically significant improvement in functional outcomes. Development was discontinued.

What were Lundbeck's FY2025 financial results?
Lundbeck reported FY2025 revenue of DKK 24.6 billion, up 13% at constant exchange rates, achieving record revenue for the fourth consecutive year. Net profit was DKK 3.2 billion. In H1 2026, revenue grew 16% at constant exchange rates to DKK 13.6 billion, with adjusted EBITDA of DKK 4.8 billion. The company maintained full-year 2026 guidance of 7-9% revenue growth.

What is the Lundbeck Foundation?
The Lundbeck Foundation was established by Grete Lundbeck in 1954 and owns approximately 70% of Lundbeck's shares. The foundation serves a dual purpose: maintaining and expanding the Lundbeck Group and funding Danish medical research. It awards approximately DKK 500 million annually to support scientific research, education, and communication activities, creating a direct link between the company's commercial success and scientific funding.